中信建投证券股份有限公司 关于北京键凯科技股份有限公司 股东向特定机构投资者询价转让股份的核查报告 上海证券交易所： 中信建投证券股份有限公司（以下简称"中信建投证券"或"组织券商"） 受委托担任 XUAN ZHAO（以下简称"出让方"）以向特定机构投资者询价转 让（以下简称"询价转让"）方式减持所持有的北京键凯科技股份有限公司 （以下简称"公司"或"键凯科技"）首次公开发行前已发行股份的组织券商。 经核查，组织券商就本次询价转让的股东、受让方是否符合《上海证券交 易所科创板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修 订）》（以下简称"《询价转让和配售指引》"）要求，本次询价转让的询价、 转让过程与结果是否公平、公正，是否符合《询价转让和配售指引》的规定作 出如下报告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 11 月 11 日，出让方所持公司股份的数量、占公司总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | XUAN ZHAO | 14,8 ...

键凯科技公告，董事长XUAN ZHAO参与本次询价转让，转让价格为76.18元/股，转让数量为181.95万 股，占总股本的3.00%。本次转让后，XUAN ZHAO及其一致行动人合计持有上市公司股份比例将从 24.56%减少至21.56%，持有公司权益比例变动触及1%的整数倍。 ...

Core Viewpoint - JianKai Technology's stock price has experienced fluctuations, with a year-to-date increase of 54.36% but a recent decline in the last five trading days by 5.13% [2] Group 1: Stock Performance - As of November 13, JianKai Technology's stock price was 87.66 CNY per share, with a market capitalization of 5.317 billion CNY [1] - The stock has seen a net outflow of 4.8918 million CNY in principal funds, with large orders buying 2.3557 million CNY (4.87%) and selling 7.2475 million CNY (14.99%) [1] - Year-to-date, the stock has been on the龙虎榜 once, with a net purchase of 39.1731 million CNY on July 21 [2] Group 2: Financial Performance - For the period from January to September 2025, JianKai Technology reported revenue of 211 million CNY, a year-on-year increase of 13.47%, and a net profit attributable to shareholders of 40.7246 million CNY, up 24.72% [2] - The company has distributed a total of 178 million CNY in dividends since its A-share listing, with 99.8755 million CNY distributed in the last three years [3] Group 3: Company Overview - JianKai Technology, established on October 9, 2001, and listed on August 26, 2020, is located in Beijing and specializes in the research, production, and sales of medical-grade polyethylene glycol and its active derivatives [2] - The company's main revenue sources are product sales (96.79%), technology usage fees (2.91%), and transportation services (0.30%) [2] - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and raw materials, with concepts including anti-cancer drugs and medical devices [2]

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688356 证券简称：键凯科技 公告编号：2025-038 北京键凯科技股份有限公司 股东询价转让定价情况提示性公告 XUAN ZHAO保证向北京键凯科技股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ● 根据2025年11月12日询价申购情况，初步确定的本次询价转让价格为76.18元/股。 ● 受让方通过询价转让受让的股份，在受让后6个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为76.18元/股。 （二）参与本次询价转让报价的机构投资者家数为17家，涵盖了基金管理公司、保险公司、证券公司、 私募基金管理人、合格境外投资者等专业机构投资者。参与本次询价转让报价的机构投资者合计有效认 购股份数量为3,308,000股，对应的有效认购倍数为1.82倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为12家机构投资者，拟受让 ...

Group 1 - The "Bohai Beautiful Bay" Industrial Innovation Development Conference was successfully held in Tianjin Economic Development Zone, marking the establishment of the Bohai Beautiful Bay Industrial Development Promotion Center, which aims to enhance the beauty industry and support high-quality development [1] - Key projects were signed during the conference, including a collaboration between JianKai Technology and Tianjin Economic Development Zone to build a medical beauty industrialization base, indicating a strategic expansion in the medical beauty sector [1][2] - JianKai Technology has been focusing on the PEG and its derivatives industry since its establishment, and is one of the few companies in China capable of producing high-purity and low-dispersity pharmaceutical-grade PEG [2] Group 2 - JianKai Technology's first medical beauty product, JK-2122H (PEG cross-linked hyaluronic acid), is expected to contribute to sales revenue in 2025, being the first domestic filler using PEG as a cross-linking agent, which offers better biocompatibility and safety [2] - The second medical beauty product, JK-1136H (water needle), has also received acceptance for its market application, which will further enrich the company's product matrix and provide new growth opportunities [2] - The collaboration within the "Bohai Beautiful Bay" initiative is expected to create a cluster of beauty and medical beauty industries, enhancing the competitive edge of JianKai Technology and driving significant growth in the high-end medical beauty market [3]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Points - JianKai Technology announced the preliminary transfer price of 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] - The transferee is prohibited from transferring the acquired shares within six months after the acquisition [1]

北京键凯科技股份有限公司 股东询价转让定价情况提示性公告 XUAN ZHAO 保证向北京键凯科技股份有限公司（以下简称"公司"）提 供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、 准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 11 月 12 日询价申购情况，初步确定的本次询价转让价格为 76.18 元/股。 受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 证券代码：688356 证券简称：键凯科技 公告编号：2025-038 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 76.18 元/股。 北京键凯科技股份有限公司董事会 2025 年 11 月 13 日 1 上海分公司最终办理结果为准。 （二）本次询价转让不涉及公司控制权变更，不会影响公司治理结构和持续 经营。 特此公告。 （二）参与本次询价转让报价的机构投资者家数为 17 家，涵盖了基金管理 公司、保险公司、证券公司、私募基金管理人、合格境外投资者等专业机构投资 者。参与本次询价转让报价的机构投资 ...

Core Viewpoint - The company JianKai Technology (688356.SH) has disclosed the pricing situation for a shareholder inquiry transfer, with a preliminary transfer price set at 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] Group 1 - The total number of shares to be transferred in this inquiry transfer is 1.8195 million shares, which has been fully subscribed [1] - The preliminary determined transferees consist of 12 institutional investors [1]

Core Viewpoint - JianKai Technology announced a preliminary inquiry transfer price of 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] Group 1: Inquiry Transfer Details - A total of 17 institutional investors participated in the inquiry transfer, including fund management companies, insurance companies, securities companies, private fund managers, and qualified foreign investors [1] - The total number of shares effectively subscribed by participating institutional investors reached 3.308 million shares, resulting in an effective subscription multiple of 1.82 times [1] - The proposed transfer shares have been fully subscribed, with a preliminary determination of 12 institutional investors as the transferees, intending to acquire a total of 1.819521 million shares [1]